Abbott Laboratories Stock Swiss Exchange
Equities
ABT
US0028241000
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
93 CHF | -.--% | -.--% | -.--% |
Apr. 29 | Abbott's Dissolving Stent Gets FDA Approval For Arteries Below the Knee | MT |
Apr. 26 | Dexcom's profit beats estimates on strong glucose monitor demand | RE |
Sales 2024 * | 41.7B 38B | Sales 2025 * | 44.75B 40.77B | Capitalization | 186B 170B |
---|---|---|---|---|---|
Net income 2024 * | 5.96B 5.43B | Net income 2025 * | 7.17B 6.53B | EV / Sales 2024 * | 4.59 x |
Net Debt 2024 * | 5.47B 4.99B | Net cash position 2025 * | 913M 832M | EV / Sales 2025 * | 4.14 x |
P/E ratio 2024 * |
31.3
x | P/E ratio 2025 * |
26.8
x | Employees | 114,000 |
Yield 2024 * |
2.02% | Yield 2025 * |
2.16% | Free-Float | 86.77% |
Latest transcript on Abbott Laboratories
6 months | +2.20% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Ford
CEO | Chief Executive Officer | 50 | 14-12-31 |
Philip Boudreau
DFI | Director of Finance/CFO | 51 | 96-12-31 |
Scott House
CTO | Chief Tech/Sci/R&D Officer | - | 89-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel Starks
BRD | Director/Board Member | 69 | 17-02-15 |
John Stratton
BRD | Director/Board Member | 63 | 17-06-28 |
Nancy McKinstry
BRD | Director/Board Member | 65 | 11-12-08 |
Date | Price | Change |
---|---|---|
24-04-29 | 93 | -.--% |
24-04-26 | 93 | -.--% |
24-04-25 | 93 | -.--% |
24-04-24 | 93 | -.--% |
24-04-23 | 93 | -.--% |
Delayed Quote Swiss Exchange, February 19, 2024 at 11:31 am EST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.85% | 106B | |
-4.26% | 66.9B | |
+1.39% | 49.45B | |
+16.82% | 48B | |
+5.59% | 40.84B | |
+3.49% | 26.48B | |
+0.65% | 26.25B | |
+17.70% | 24.62B | |
+0.01% | 24.52B |
- Stock Market
- Equities
- ABT Stock
- ABT Stock